Posted by Michael Wonder on 27 Jan 2016
Health Canada approves PrOrkambi (lumacaftor/ivacaftor) - the first medicine to treat the underlying cause of cystic fibrosis for people ages 12 and older with two copies of the F508del mutation
26 January 2016 - Approximately 1,500 people in Canada are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease.
For more details, go to: http://investors.vrtx.com/releases.cfm?hdr02=press
